Screener / SEC EDGAR /CIK 0001711279 /10-K filed Feb 17, 2026, compared with Feb 19, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Biotechnology

Krystal Biotech, Inc. KRYS

Compare with peers Embed
Why it changed

The biggest changes in the 10-K filed Feb 17, 2026, in management's words

10-K, Item 7

This fiscal year against the last, and the sentences in the MD&A where management explains each change. Tickdelta picks sentences that name the line, a direction and a cause. It does not write explanations of its own.

Operating margin

Big change, FY to Dec 31, 2025 vs Dec 31, 2024

22.6% to 41.5% (+18.8 pts)

The MD&A has no sentence that names a cause for this change.

Net income

Big change, FY to Dec 31, 2025 vs Dec 31, 2024

+129.7%

“The decrease in interest and other income for the year ended December 31, 2025 compared to the year ended December 31, 2024 is primarily the result of the effects of foreign exchange rates.”

Read it in the 10-K

Cash from operations

Big change, FY to Dec 31, 2025 vs Dec 31, 2024

+62.7%

“Net cash provided by operating activities for the year ended December 31, 2025 was $200.9 million and consisted primarily of net income of $204.8 million adjusted for $32.5 million of non-cash items and a $36.4 million decrease in cash due to an increase in net working capital.”

Read it in the 10-K

Revenue

Big change, FY to Dec 31, 2025 vs Dec 31, 2024

+33.9%

“The increase in product revenue, net from 2024 to 2025 was driven by an increase in VYJUVEK sales as compared to the prior year.”

Read it in the 10-K

What management said, year by year

The cause given in each 10-K, 2 fiscal years, newest first · MD&A (Item 7)

Each bar is how the line changed that year (from the same 10-K's XBRL). Under it, the sentence in that year's MD&A that names the line, a direction and a cause, word for word. A year with no sentence says so.

Revenue

2 of 2 years explained
  • FY 2025 +33.9%

    “The increase in product revenue, net from 2024 to 2025 was driven by an increase in VYJUVEK sales as compared to the prior year.”

    Read it in the FY 2025 10-K
  • FY 2024 +473.0%

    “The increase in product revenue, net from 2023 to 2024 was driven by an increase in VYJUVEK sales following initial commercial sales recorded in August 2023.”

    Read it in the FY 2024 10-K

Operating margin

1 of 2 years explained
  • FY 2025 +18.8 pts

    The FY 2025 MD&A has no sentence that names a cause for this change.

  • FY 2024 +239.0 pts

    “an increase of $3.6 million in other research and development expenses primarily relating to licensing and regulatory costs and facilities and equipment related costs, and”

    Read it in the FY 2024 10-K

    “an increase of $428 thousand in other research and development expenses, primarily due to increases in facilities expenses.”

    Read it in the FY 2024 10-K

Net income

1 of 2 years explained
  • FY 2025 +129.7%

    “The decrease in interest and other income for the year ended December 31, 2025 compared to the year ended December 31, 2024 is primarily the result of the effects of foreign exchange rates.”

    Read it in the FY 2025 10-K
  • FY 2024 +715.6%

    The FY 2024 MD&A has no sentence that names a cause for this change.

Changes are computed from the XBRL figures in the same 10-K. Hover a number to see the line item. Open the 10-K

Sources

The Management's Discussion and Analysis (Item 7) of the latest 10-K, quoted word for word; the changes are computed from the same 10-K's XBRL.

Also

Financials: the numbers year by year.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/KRYS/export.csv") into a cell.

Next:Accounting checks
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.